DLBCL Video Channel
Explore the latest insights and summaries from experts in Diffuse Large B-Cell Lymphoma.
Therapeutic Agents
SOHO Brazil 2024
What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy in LBCL?
FEATURING
Andrew Zelenetz
- 57 views
- July 11, 2024
UChicago Medicine
Bispecifics for LBCL: Guidance for Management of Toxicities in the Community
FEATURING
Jennifer Crombie
- 163 views
- July 29, 2024
- 3
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
FEATURING
Julie Erika Haydu
- 308 views
- June 5, 2024
- 3
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
FEATURING
Julio Chavez
- 826 views
- March 4, 2024
- 4
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
- 343 views
- June 26, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Management With Bispecific Agents in MM and B-Cell NHL"
FEATURING
Monique Minnema
- 284 views
- June 7, 2024
- 4
UChicago Medicine
Understanding CRISPR and Gene Editing in the Treatment of Heme Malignancies and Blood Disorders
FEATURING
Alan Cooper
- 252 views
- July 29, 2024
Juan Pablo Alderuccio
Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial
- 228 views
- July 8, 2024
- 1
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 241 views
- April 30, 2024
- 2
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
FEATURING
Robert Peter Gale
- 509 views
- February 21, 2024
- 2
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 194 views
- June 28, 2024
- 3
Indy Hematology Review
Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do and Know in Community Oncology Practice
FEATURING
Tycel Phillips
- 152 views
- April 23, 2024
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 236 views
- July 22, 2024
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A Practical Guide for the Community Oncologist
- 479 views
- February 22, 2024
- 2
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
FEATURING
Aleksandr Lazaryan
- 332 views
- March 11, 2024
- 1
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 286 views
- September 19, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies
FEATURING
Maher Salamoon
- 124 views
- July 9, 2024
- 2
SOHO Brazil 2024
Summary of Updates in R/R DLBCL Treatment
FEATURING
Alvaro Alencar
- 108 views
- July 11, 2024
Yale Cancer Center
Updates on Cellular Therapy Advances in Lymphoma
FEATURING
Iris Isufi
- 86 views
- May 15, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Cell Therapy
FEATURING
Marcos de Lima
- 183 views
- March 26, 2024
- 3
Gerardo Musuraca
Managing R/R DLBCL: Bispecific Antibodies and the "Surface Epitopes Strategy"
- 70 views
- June 17, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-Up Comparing Liso-Cel vs. SoC With Salvage Chemo and ASCT as 2L Treatment in R/R LBCL"
FEATURING
Manali Kamdar
- 76 views
- June 20, 2024
MyCancerHaven
How I Use CAR T-Cells in Lymphoma
FEATURING
Ravi Vij,
Abhinav Deol
- 61 views
- April 10, 2024
MyCancerHaven
Experts Discuss the Use of CAR-T in 2L DLBCL
FEATURING
Ravi Vij,
Dipenkumar Modi
- 65 views
- August 30, 2024
James Essell
Bringing CAR-T for Hematologic Malignancies to the Community Practices
- 59 views
- June 20, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Future of Treatment for DLBCL: Molecular-Based or Immunotherapies?
FEATURING
Gerardo Musuraca
- 64 views
- February 21, 2024
- 1
Joseph McGuirk
Liso-Cel in R/R DLBCL: Real-World Insights From the Cell Therapy Consortium
- 52 views
- August 27, 2024
Total Health
Update on Cellular Therapy in Lymphoma
FEATURING
Brion Randolph
- 114 views
- February 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Overview of Biscpecific Antibodies in Hematologic Malignancies
FEATURING
Bahar Uncu Ulu
- 50 views
- August 15, 2024
Patrizia Mondello
Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLBCL
- 180 views
- September 30, 2024
MyCancerHaven
Recent Updates on Liso-Cel in R/R DLBCL & MCL
FEATURING
Ravi Vij,
Forat Lutfi
- 44 views
- August 30, 2024
ecancer
ASH 2023 Insights: "Niveau Trial - Nivolumab + R-GemOx Followed by Nivo Maintenance in R/R LBCL"
FEATURING
Gerhard Held
- 45 views
- January 18, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Updated Trends in Real-World Outpatient Administration of CAR-T in R/R NHL
FEATURING
Radhika Bansal
- 36 views
- June 30, 2024
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 48 views
- July 22, 2024
- 1
UChicago Medicine
The Evolving Role for Bispecific Antibodies in B-Cell Lymphoma
FEATURING
Tara Mccabe
- 42 views
- July 29, 2024
GRACE
Epcoritamab in NHL - Incidence and Management of CRS
FEATURING
Tycel Phillips
- 172 views
- February 16, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients With Untreated Aggressive B-Cell Lymphoma
FEATURING
Marc Hoffmann
- 32 views
- July 18, 2024
Vanderbilt University Medical Center (VUMC)
CAR-T for Lymphoma: The Impact of Cell Therapy and Future Challenges
FEATURING
Sattva Neelapu
- 27 views
- July 18, 2024
Rush University Medical Center
Off the Shelf CARs for DLBCL: Myths and Facts
FEATURING
Veronika Bachanova
- 28 views
- June 6, 2024
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
GRACE
Current Utility of Autologous Bone Marrow Transplants in Myeloma and Lymphoma
FEATURING
Marco Ruiz
- 41 views
- February 15, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
CAR-T and Bispecifics in Lymphoma: Updates on the Evolving Role of Immune Modulating Therapies
FEATURING
Sunita D. Nasta
- 36 views
- March 13, 2024
GRACE
Efficacy of Epcoritamab and Glofitamab in R/R DLBCL
FEATURING
Tycel Phillips
- 41 views
- February 16, 2024
GRACE
The Impact of Transplant on Survival in Myeloma and Lymphoma
FEATURING
Marco Ruiz
- 27 views
- February 15, 2024
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Ph2 EpiRCHOP Study - Tazemetostat With R-CHOP in Elderly 1L DLBCL"
FEATURING
Clementine Sarkozy
- 106 views
- December 28, 2023
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current Status and Future Directions for CAR T-Cell Therapy
FEATURING
Jean-Francois Rossi
- 27 views
- February 16, 2024
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 18 views
- July 22, 2024
ImmunoTherapy Bridge 2023
Surviving in the Lymphoma Microenvironment: A Tough Challenge for CAR T-Cells
FEATURING
Marco Ruella
- 51 views
- January 10, 2024